RE:Real & Camo Please elaborate on potential partners and when I realize that few investors read financial statements and more importantly, management reports.
To answer your question about the brith future of Liminal I will quote some statement from the last quarter report ended march31 2020.
Page 7 about risk in the very close futur..
Until the Company completes a significant financing, it continues operating at a low spending level, pacing investments on new research programs, and reducing infrastructure cost where possible. The need to complete multiple financing transactions is likely to continue until the Company can generate sufficient product revenues to finance its cash requirements. Meanwhile, management expects to finance future cash needs primarily through a combination of public or private equity offerings, debt financings, strategic collaborations, business and asset divestitures, and grant funding. Despite the Company’s efforts to obtain the necessary funding and improve profitability of its operations, there can be no assurance of its success in doing so, especially with respect to its access to further funding on acceptable terms, if at all, particularly if the COVID-19 pandemic continues to disrupt global financial markets.
These circumstances indicate the existence of a material uncertainty that may cast significant doubt about the Company’s ability to continue as a going concern. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s preclinical, clinical and regulatory efforts, which are critical to the realization of its business plan. These unaudited condensed interim consolidated financial statements do not
include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.
Even if the new management lost a lot of money..$240M in 2019 and $30 Q1 2020 the board decided to decrese price exercise of warants granted to directors (ex:880 000 for Galbraith) from $36 to $15 !!! The majority of board memebers never bougt shares on the market !!!
Talking about futur...In 2019 financial statements they declare that they stoped R&D in Ryplazim for wound healing in diabeties exactly were the big business is.
Do your DD and good lock. Don't forget that there will be at least 2 lawsuits.